{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:52:54Z","timestamp":1780368774874,"version":"3.54.1"},"reference-count":21,"publisher":"MathDoc\/Centre Mersenne","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p id=\"spar0005\">Due to its oral route of administration and mild toxicity profile, as well as its potent laboratory and clinical effects, hydroxyurea (or hydroxycarbamide) has been the primary focus of fetal hemoglobin (HbF) induction strategies for the treatment of children with sickle cell anemia (SCA). When administered orally once a day, hydroxyurea treatment is very well tolerated with little short-term toxicity. Hydroxyurea has documented laboratory efficacy with increases in Hb and HbF; treatment also significantly reduces the number of painful episodes, acute chest syndrome, transfusions, and hospitalizations. Most young patients reach a maximum tolerated dose of hydroxyurea at 25\u201330\u2005mg\/kg\/d, where they will achieve key laboratory thresholds (Hb\u2005\u2265\u20059\u2005g\/dL and HbF\u2005\u2265\u200520%) without excessive myelosuppression. Potential long-term toxicities continue to be of great concern and should be monitored in all patients with SCA who receive hydroxyurea therapy. To date, however, no increases in stroke, myelodysplasia, or carcinogenicity have been detected in SCA patient cohorts, with drug exposure now reaching 15\u2005years for some treated children. Taken together, available evidence suggests that hydroxyurea represents an inexpensive and effective treatment option that should be offered to most, if not all, patients with SCA. As countries in Africa develop newborn screening programs to identify SCA, the widespread use of hydroxyurea may prove to be a useful treatment to help ameliorate the disease in resource-limited settings. Hydroxyurea is the only currently available disease-modifying therapy for SCA, and is emerging as a safe and effective treatment for all patients with SCA, in both developed and developing countries.<\/jats:p>","DOI":"10.1016\/j.crvi.2012.09.006","type":"journal-article","created":{"date-parts":[[2012,11,9]],"date-time":"2012-11-09T00:45:31Z","timestamp":1352421931000},"page":"177-182","source":"Crossref","is-referenced-by-count":18,"title":["Hydroxycarbamide: Clinical aspects"],"prefix":"10.5802","volume":"336","author":[{"given":"Russell E.","family":"Ware","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3842","published-online":{"date-parts":[[2012,11,8]]},"reference":[{"issue":"5","key":"key2025102316363920337_1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00043426-199909000-00013","article-title":"Physiologic decline in fetal hemoglobin parameters in infants with sickle cell disease: implications for pharmacological intervention","volume":"21","author":"Marcus, S.J.","year":"1999","unstructured":"[1] Marcus, S.J.; Ware, R.E. Physiologic decline in fetal hemoglobin parameters in infants with sickle cell disease: implications for pharmacological intervention, J. Pediatr. Hematol.\/Oncol., Volume 21 (1999) no. 5, pp. 407-411","journal-title":"J. Pediatr. Hematol.\/Oncol."},{"issue":"8","key":"key2025102316363920337_2","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/archpedi.1994.02170080026005","article-title":"Reference values and hematologic changes from birth to 5\u2005years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease","volume":"148","author":"Brown, A.K.","year":"1994","unstructured":"[2] Brown, A.K.; Sleeper, L.A.; Miller, S.T.; Pegelow, C.H.; Gill, F.M.; Waclawiw, M.A. Reference values and hematologic changes from birth to 5\u2005years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease, Arch. Pediatr. Adolesc. Med, Volume 148 (1994) no. 8, pp. 796-804","journal-title":"Arch. Pediatr. Adolesc. Med"},{"issue":"11","key":"key2025102316363920337_3","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/archpedi.1993.02160350071011","article-title":"Sickle cell anemia. Beta-S gene cluster haplotypes as genetic markers for severe disease expression","volume":"147","author":"Powars, D.","year":"1993","unstructured":"[3] Powars, D.; Hiti, A. Sickle cell anemia. Beta-S gene cluster haplotypes as genetic markers for severe disease expression, Am. J. Dis. Child., Volume 147 (1993) no. 11, pp. 1197-1202","journal-title":"Am. J. Dis. Child."},{"issue":"33","key":"key2025102316363920337_4","doi-asserted-by":"crossref","first-page":"11869","DOI":"10.1073\/pnas.0804799105","article-title":"DNA polymorphism at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease","volume":"105","author":"Lettre, G.","year":"2008","unstructured":"[4] Lettre, G.; Sankaran, V.G.; Bezerra, M.A. et al. DNA polymorphism at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease, Proc. Natl Acad. Sci. USA, Volume 105 (2008) no. 33, pp. 11869-11874","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"2","key":"key2025102316363920337_5","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1172\/JCI111464","article-title":"Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia","volume":"74","author":"Platt, O.S.","year":"1984","unstructured":"[5] Platt, O.S.; Orkin, S.H.; Dover, G.; Beardsley, G.P.; Miller, B.; Nathan, D.G. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia, J. Clin. Invest., Volume 74 (1984) no. 2, pp. 652-656","journal-title":"J. Clin. Invest."},{"issue":"26","key":"key2025102316363920337_6","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1182\/blood-2009-04-146852","article-title":"How I use hydroxyurea to treat young patients with sickle cell anemia","volume":"115","author":"Ware, R.E.","year":"2010","unstructured":"[6] Ware, R.E. How I use hydroxyurea to treat young patients with sickle cell anemia, Blood, Volume 115 (2010) no. 26, pp. 5300-5311","journal-title":"Blood"},{"issue":"20","key":"key2025102316363920337_7","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia: investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia","volume":"332","author":"Charache, S.","year":"1995","unstructured":"[7] Charache, S.; Terrin, M.L.; Moore, R.D. et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia: investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia, N. Engl. J. Med., Volume 332 (1995) no. 20, pp. 1317-1322","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"key2025102316363920337_8","first-page":"1550","article-title":"Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I\/II trial. Pediatric Hydroxyurea Group","volume":"94","author":"Kinney, T.R.","year":"1999","unstructured":"[8] Kinney, T.R.; Helms, R.W.; O\u2019Branski, E.E. et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I\/II trial. Pediatric Hydroxyurea Group, Blood, Volume 94 (1999) no. 5, pp. 1550-1554","journal-title":"Blood"},{"issue":"9778","key":"key2025102316363920337_9","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicenter, randomized, controlled trial (BABY HUG)","volume":"377","author":"Wang, W.C.","year":"2011","unstructured":"[9] Wang, W.C.; Ware, R.E.; Miller, S.T. et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicenter, randomized, controlled trial (BABY HUG), Lancet, Volume 377 (2011) no. 9778, pp. 1663-1672","journal-title":"Lancet"},{"issue":"6","key":"key2025102316363920337_10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1067\/mpd.2001.119590","article-title":"A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia","volume":"139","author":"Wang, W.C.","year":"2001","unstructured":"[10] Wang, W.C.; Wynn, L.W.; Rogers, Z.R.; Scott, J.P.; Lane, P.A.; Ware, R.E. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia, J. Pediatr., Volume 139 (2001) no. 6, pp. 790-796","journal-title":"J. Pediatr."},{"issue":"2","key":"key2025102316363920337_11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.pcl.2008.02.003","article-title":"Hydroxyurea for children with sickle cell disease","volume":"55","author":"Heeney, M.M.","year":"2008","unstructured":"[11] Heeney, M.M.; Ware, R.E. Hydroxyurea for children with sickle cell disease, Pediatr. Clin. North Am., Volume 55 (2008) no. 2, pp. 483-501","journal-title":"Pediatr. Clin. North Am."},{"key":"key2025102316363920337_12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/asheducation-2009.1.62","article-title":"Advances in the use of hydroxyurea","author":"Ware, R.E.","year":"2009","unstructured":"[12] Ware, R.E.; Aygun, B. Advances in the use of hydroxyurea, Am. Soc. Hematol. Educ. Program (2009), pp. 62-69","journal-title":"Am. Soc. Hematol. Educ. Program"},{"issue":"10","key":"key2025102316363920337_13","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood.V79.10.2555.2555","article-title":"Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia","volume":"79","author":"Charache, S.","year":"1992","unstructured":"[13] Charache, S.; Dover, G.J.; Moore, R.D. et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia, Blood, Volume 79 (1992) no. 10, pp. 2555-2565","journal-title":"Blood"},{"issue":"17","key":"key2025102316363920337_14","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1182\/blood-2011-11-392340","article-title":"For the SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH)","volume":"119","author":"Ware, R.E.","year":"2012","unstructured":"[14] Ware, R.E.; Helms, R.W. For the SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH), Blood, Volume 119 (2012) no. 17, pp. 3925-3932","journal-title":"Blood"},{"issue":"4","key":"key2025102316363920337_15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ajh.10427","article-title":"Malignancy in sickle cell disease","volume":"74","author":"Schultz, W.H.","year":"2003","unstructured":"[15] Schultz, W.H.; Ware, R.E. Malignancy in sickle cell disease, Am. J. Hematol., Volume 74 (2003) no. 4, pp. 249-253","journal-title":"Am. J. Hematol."},{"issue":"10","key":"key2025102316363920337_16","first-page":"1046","article-title":"Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia","volume":"101","author":"Ballas, S.K.","year":"2009","unstructured":"[16] Ballas, S.K.; McCarthy, W.F.; Guo, N. et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia, J. Natl Med. Assoc., Volume 101 (2009) no. 10, pp. 1046-1051","journal-title":"J. Natl Med. Assoc."},{"issue":"6","key":"key2025102316363920337_17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajh.21699","article-title":"The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5-year follow-up","volume":"85","author":"Steinberg, M.H.","year":"2010","unstructured":"[17] Steinberg, M.H.; McCarthy, W.F.; Castro, O. et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5-year follow-up, Am. J. Hematol., Volume 85 (2010) no. 6, pp. 403-408","journal-title":"Am. J. Hematol."},{"issue":"12","key":"key2025102316363920337_18","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2009-05-221333","article-title":"The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)","volume":"115","author":"Voskaridou, E.","year":"2010","unstructured":"[18] Voskaridou, E.; Christoulas, D.; Bilalis, A. et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS), Blood, Volume 115 (2010) no. 12, pp. 2354-2363","journal-title":"Blood"},{"issue":"22","key":"key2025102316363920337_19","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2010-01-251348","article-title":"The inherited diseases of hemoglobin are an emerging global health burden","volume":"115","author":"Weatherall, D.J.","year":"2010","unstructured":"[19] Weatherall, D.J. The inherited diseases of hemoglobin are an emerging global health burden, Blood, Volume 115 (2010) no. 22, pp. 4331-4336","journal-title":"Blood"},{"issue":"18","key":"key2025102316363920337_20","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2011-07-364190","article-title":"Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia","volume":"118","author":"Ware, R.E.","year":"2011","unstructured":"[20] Ware, R.E.; Despotovic, J.M.; Mortier, N.A. et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia, Blood, Volume 118 (2011) no. 18, pp. 4985-4991","journal-title":"Blood"},{"issue":"3","key":"key2025102316363920337_21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/MOH.0b013e32834521dd","article-title":"Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?","volume":"18","author":"McGann, P.T.","year":"2011","unstructured":"[21] McGann, P.T.; Ware, R.E. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?, Curr. Opin. Hematol., Volume 18 (2011) no. 3, pp. 158-165","journal-title":"Curr. Opin. Hematol."}],"container-title":["Comptes Rendus. Biologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/comptes-rendus.academie-sciences.fr\/biologies\/item\/10.1016\/j.crvi.2012.09.006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T14:49:34Z","timestamp":1761230974000},"score":1,"resource":{"primary":{"URL":"https:\/\/comptes-rendus.academie-sciences.fr\/biologies\/articles\/10.1016\/j.crvi.2012.09.006\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,8]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013]]}},"alternative-id":["10.1016\/j.crvi.2012.09.006"],"URL":"https:\/\/doi.org\/10.1016\/j.crvi.2012.09.006","relation":{},"ISSN":["1631-0691","1768-3238"],"issn-type":[{"value":"1631-0691","type":"print"},{"value":"1768-3238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,8]]}}}